Status
Conditions
Treatments
About
The purpose of this study is to confirm that prognosis of Intrahepatic Cholangiocarcinoma (ICC) with resection and radiotherapy ,to find which is safe and effective treatment.
Full description
Intrahepatic Cholangiocarcinoma (ICC), the second most common primary liver cancer and constitutes 10% of primary liver malignancies.
Current therapies for the treatment of ICC are ineffective and the role of liver transplantation is not well defined.
This study reviews our experience with this tumor and looks for preoperative and pathologic indices that may help determine long term prognosis
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
No dysfunction in major organs; Blood routine, kidney function, cardiac function and lung function are basically normal. Hbg ≥ 90g/L, WBC ≥ 3.000 cells/mm³,platelets ≥ 80.000 cells/mm³.
Karnofsky Performance Score performance over 60. Patients who can understand this trial and have signed information consent.
Exclusion criteria
Patients with other diseases which may affect the treatment mentioned here. Patients with medical history of other malignant tumors. Subjects participating in other clinical trials. Extrahepatic metastasis, portal vein or other major vascular involvement. liver function: Child B C.
Patients would not sign the consent to the trial.
Primary purpose
Allocation
Interventional model
Masking
200 participants in 2 patient groups
Loading...
Central trial contact
Yuan Hang; Li Aijun, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal